

Protective non-neutralizing mAbs targets conserved opsonic epitopes on SARS-CoV-2 variants

Arman Izadi¹, Magdalena Godzwon², Mats Ohlin^{2,3}, Pontus Nordenfelt^{1,4*}

¹*Department of Clinical Sciences Lund, Division of Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden*

²*Department of Immunotechnology, Lund University, Lund, Sweden*

³*SciLifeLab Drug Discovery and Development, Lund University, Lund, Sweden*

⁴*Department of Laboratory Medicine, Clinical Microbiology, Skåne University Hospital Lund, Lund University, Lund, Sweden*

*Pontus Nordenfelt, Corresponding author

Email: pontus.nordenfelt@med.lu.se

Author Contributions:

Arman Izadi conceptualized the study, performed experiments, analyzed data, and wrote the original draft. Magdalena Godzwon performed experiments and analyzed data and edited the final draft. Mats Ohlin conceptualized the study and edited the final draft. Pontus Nordenfelt conceptualized the study and wrote the original draft with Arman Izadi.

Competing Interest Statement: Arman Izadi and Pontus Nordenfelt has filed a patent pending for the antibodies described in this manuscript with Tanea Ab.

Classification: COVID-19, Immunology and inflammation, Microbiology

Keywords: COVID-19, antibodies, IgG3, phagocytosis, SARS-CoV-2

This PDF file includes:

Main Text
Figures 1 to 3

Abstract

Antibodies play a central role in the immune defense against SARS-CoV-2. Strong evidence has shown that non-neutralizing antibodies (nnAbs) are important for anti-SARS-Cov-2 immunity through Fc-mediated effector functions. These nnAbs bind to epitopes that could be less subjected to mutations in the emerging variants. When protective, such nnAbs would constitute a more promising alternative to neutralizing mAbs (nAbs). Here, we show that six nnAbs retain binding to Omicron, while two nAbs do not. Furthermore, two of our nnAbs, which are protective *in vivo*, retained binding to XBB, XBB.1.5, and BQ.1.1. They appear to bind to conserved epitopes on the N-terminal and receptor binding domain (RBD), respectively. As a proof of concept, we show that these protective non-neutralizing antibodies retain potent Fc-mediated opsonic function against BQ.1.1 and XBB. We also show that the Fc-mediated function is further enhanced by expressing the antibodies in the IgG3 subclass and combining them into a dual antibody cocktail. Our work suggests that opsonizing nnAbs could be a viable strategy for anti-SARS-CoV-2 mAb therapies against current and future SARS-CoV-2 variants.

Introduction

SARS-CoV-2 has caused millions of deaths worldwide since it first emerged in 2019¹. Early in the pandemic, monoclonal antibodies (mAbs) were successfully used as therapeutics². These antibodies disrupted the ACE2 receptor-spike receptor-binding domain (RBD) interaction, thus neutralizing the virus and protecting the host³. However, with the emergence of variants, in particular Omicron the antibodies mostly lost the ability to neutralize the virus⁴⁻⁵. None of the clinically approved antibodies are functionally active against the emerging omicron subvariants XBB and BQ1.1⁶. The reason for this loss of function in these neutralizing antibodies (nAbs) was primarily the extensive mutations in the RBD present across the Omicron subvariants, at sites that most nAbs target. The emergence of these variants has led researchers to focus on generating pan-neutralizing antibodies⁷⁻⁸. It remains to be seen whether this strategy will be successful against future variants of SARS-CoV-2.

Antibodies with potent Fc-mediated function have not been given the same level of attention as neutralizing antibodies. Recently, we have shown that two potent opsonizing antibodies, Ab81 and Ab94, targeting the RBD and N-terminal domain (NTD), respectively, strongly protect against the Wuhan strain in transgenic K-18 mice⁹⁻¹⁰. Notably, these antibodies are non-neutralizing (nnAbs), mediating their protective effect through Fc-mediated effector functions. Other emerging findings with convalescent sera or neutralizing antibodies with modified Fc-effector functions align with our previous results, showing that Fc-effector functions are crucial for anti-SARS-CoV-2 viral control¹¹⁻¹⁴. The protection granted by vaccines against severe disease by mutated variants like Omicron can be partially explained by intact antibody Fc-effector functions directed against non-RBD sites¹⁵. Thus, a viable strategy complementing the pan-universal neutralizing antibody approach would be to generate opsonic antibodies against conserved epitopes, avoiding the RBD- and NTD-sites targeted by most neutralizing antibodies.

To validate the approach of using opsonizing anti-spike antibodies as a potential therapy against Omicrons sub-variants and, in extension, future variants, we tested the reactivity of 8 clones generated against the Wuhan strain⁹. We showed that of our 8 antibody clones, generated previously against the Wuhan strain, 6 retain unaltered binding against the Omicron, BA2, BA4, and BA5. Bioinformatics analysis showed that the NTD-binding clone 94 binds to a conserved epitope across spike variants. Only the two nAbs, clones 57 and 59, lost binding against Omicron. We further analyzed the affinity of clones 81 and 94 against the more recent variants XBB, BQ.1.1, and XBB.1.5, where we observed that they retain nanomolar affinity comparable to the Wuhan spike protein. Finally, we show that both subclasses IgG1 and IgG3 of clones 81 and 94 show strong Fc-mediated phagocytosis against the newer XBB and BQ1.1 variants. Like in our recent work, the cocktail approach of Ab81 and Ab94 in conjunction generated the most potent functional output and is thus a promising candidate as therapeutic against these variants and possibly future variants.

Results

Potent anti-NTD Ab94 binds to a conserved opsonic site unaltered by mutations in current circulating variants

In previous work, we established a set of antibodies from B cells of previously SARS-CoV-2-infected subjects. Of these, Ab94 binds to the NTD of the Wuhan spike protein, and the other clones bind to the RBD⁹. In terms of neutralizing epitopes in the NTD, five sites are known to be targeted by most anti-NTD nAbs: residues 14-26, 67-79, 141-156, 177-186, and 246-260 (N1-N5 loops)¹⁶⁻¹⁷. Furthermore, residues 14-20, 140-158, and 245-264 have been identified as antigen supersites for anti-NTD nAbs¹⁶⁻¹⁷. The spike protein has undergone substantial mutations in the RBD and NTD of the S1 subunit (**Fig. 1A-B**). Cross-link data from TX-MS showed that Ab94 binds to an epitope at amino acid residues G35-F43 in the S1 unit of the NTD⁹ which is a non-neutralizing epitope close to the NTD-loop 1 (**Fig. 1C**). To understand if Ab94's binding-epitope is conserved, or at least has not been subjected to mutations, we analyzed the mutations in the spike glycoprotein in the variants up to XBB1.5, XBB1.16, XBB1.9, XBB.2.3X, CH1.1, BQ1.1 and compared it to the European original strain B1 (**Supp. Fig. 1**).

Interestingly, although the spike protein has undergone extensive mutations in both the RBD and NTD, the epitope of Ab94 has not been subjected to mutations (**Fig. 1A-C**). The most proximal alteration is the exchange of Leucine in residue 24 to Serine and deletion of amino acids 25-27, which emerged in the BA.2 and BA.5 variants (**Supp. Fig 1**)⁶. Furthermore, BA.2 developed into XBB and added mutations in the NTD with V83A, del144, H146Q, and Q183E⁶. XBB1.5 added further mutation in G252V (**Supp. Fig 1**). While the BQ.1.1 (developed from BA.5) and CH1.1 (developed from BA.2) both underwent a mutation in G142D⁶. BQ1.1 had a deletion in amino acid residues 69/70 (**Supp. Fig 1**). CH.1.1 exhibited more extensive mutation compared to BQ1.1 with mutations in K147E, W152R, F157L, I210V, V213G and G257S (**Supp. Fig 1**). Though CH1.1 lacked the mutations in V83A, del144, mutation H146Q, and Q183E shown by XBB and XBB.1.5, which in turn lack the mutations K147E, W152R, F157L that CH1.1 has. XBB1.16 has a mutation in E180V, which is not shared by the other XBB sublineages, and XBB2.3 has a unique mutation in D253G. Finally, the latest variant (august 2023) EG.5.1, has a substitution mutation Q52H. Thus, Ab94's target epitope G35-F43 has not been subjected to any mutation in the variants from Wuhan up to XBB.1.5, XBB.1.16, XBB1.19, XBB.1.9.2 XBB.2.3X, CH.1.1 and EG.5.1 respectively. This is contrary to most anti-NTD nAbs that target these neutralizing antigen sites, which have all undergone mutations in the XBB sublineages¹⁶⁻¹⁷ (**Fig. 1A-C**).

Since anti-NTD and anti-RBD nAbs target sites that interact with the ACE2-receptor, they are constrained to specific interacting epitopes, which have now undergone extensive mutations. Opsonizing nAbs, such as Ab94, are seemingly less influenced by this issue since a vast majority of the spike residues are not mutated (**Fig. 1C**). Additionally, while 6 out of 8 mAbs tested are not neutralizing, all eight mediate strong opsonic function, indicating that the requirements for opsonic function are less demanding based on epitope specificity. Finally, our analysis strongly suggests that Ab94 binds a conserved site since it has not undergone mutations in the circulating viral variants during the three years since its identification. Still, the binding and protective function of this nAb might be lost since mutations in other sites might influence epitopes both proximally and distally due to allosteric changes.

Non-neutralizing antibodies retain binding against Omicron and sub-variants up until BQ.1.1, XBB and XBB.1.5

To validate our bioinformatic and epitope analysis on the target epitope of Ab94, we assessed its reactivity to the Omicron and BA.2, BA.4, and BA.5 sublineages. Although we do not have complete information on the epitope sites for our anti-RBD nAbs (clones 11, 36, 66, 77, and 81), we wanted to use these as well to test the hypothesis of using nAbs to target, theoretically, less mutation-prone epitopes. In previous work, we used spike-coated microsphere beads to assess the reactivity of our mAbs against the Wuhan spike protein⁹⁻¹⁰. Here, using the same approach, we incubated

spike-coated microsphere beads (coated with Wuhan, Omicron, BA.2, BA.4, and BA.5 spike protein) with our anti-spike antibodies. We assessed reactivity by adding fluorescent anti-Fab secondary antibodies (**Supp. Fig. 2A**). We analyzed IgG binding to the spike-coated beads with flow cytometry as done previously⁹⁻¹⁰. All clones were analyzed as IgG3 except for Ab11, which was in the IgG1 subclass since it exhibited diminished affinity in the IgG3 subclass prior. Of the 8 clones, which are strongly reactive to the Wuhan spike protein (**Fig. 1D**), 6 exhibited strong binding to the Omicron variant (**Fig. 1E**). Interestingly, only the antibody clones that were neutralizing the Wuhan variant, Ab57 and Ab59, were those that lost binding to the Omicron variant. Contrary to those, the nnAbs 11, 36, 66, 77, 81, and 94 retained strong reactivity. The same result was seen for the Omicron sub-variants BA2, BA4, and BA5 (**Fig. 1F-H**), reinforcing that opsonic antibodies can potentially bind to conserved epitopes.

To further investigate the binding kinetics of our clones towards the spike variants, we performed surface plasmon resonance assays (SPR) with the multivalent spike trimer as done previously¹⁰. For these assays, we chose to focus on clones 66, 77, 81, and 94 in the IgG3 subclass since these clones were shown to have potent *in vitro* Fc effector functions previously in this subclass¹⁰. The results showed that the apparent dissociation constant (K_D) and association rate constant (k_A) are equivalent for all tested clones when comparing the reactivity towards the Wuhan spike protein and the variants Omicron, BA.2, BA.4 and BA.5 (**Fig. 2A-D, Fig. 2E**). The only exception is clone 94 which, interestingly, binds with higher avidity towards all the variants compared to WT (**Fig. 2D-E**). We further analyzed the avidity of clones 81 and 94 against the newer variants BQ.1.1 and XBB. We focused on these two clones since they were both shown to be protective against a lethal Wuhan infection in a K18-hACE2 mouse model⁹⁻¹⁰. These SPR experiments showed that both clones retain a high affinity towards BQ1.1 and XBB (**Fig. 2F-G**). Ab94 binds with similar avidity to XBB as to the Wuhan spike (k_A and K_D) but binds 5-fold better to BQ1.1 (**Fig. 2F-G**). Finally, we analyzed the binding ability of clone 81 against the RBD of XBB 1.5 due to its mutation in the RBD site F486P. This experiment showed a similar result that Ab81 has a sub-nanomolar affinity towards even this mutated variant of XBB (**Fig. 2F-G**) comparable to the affinity to Wuhan RBD measured previously¹⁰. We did not analyze Ab94 for this variant since the difference in mutational profile between it and XBB is identical when the NTD is concerned. Taken together, our results show that our opsonic nnAbs retain strong binding to variants that emerged from Omicron while our nAbs clones did not. Finally, the protective clones Ab81 and Ab94 seemingly bind to epitopes that allow Ab81 to retain nanomolar binding against these heavily mutated spike trimer variants. Ab94 seems to bind even better to the mutated variants, except for XBB, which is comparable to the WT spike. Ab94 is thus seemingly binding to a conserved epitope.

Both IgG1 and IgG3 subclasses of clones 81 and 94 show potent Fc-mediated phagocytosis against the BQ1.1 variant

Having established our clones' binding properties, we decided to investigate if this translates to intact *in vitro* effector functions in the form of Fc-mediated phagocytosis. We opted to test their function on BQ.1.1 spike trimer-coated microsphere beads. We have previously shown that our mAbs are opsonic in a flow cytometry-based phagocytosis assay of spike beads with the THP-1 cell line⁹⁻¹⁰ and that the results are relevant for biological protection *in vivo*. First, we tested the individual mAbs in both IgG1 and IgG3 subclasses for clones 81 and 94. We looked at the percentage of cells that were bead-positive and the median signal for beads in this population, which is a metric for bead quantity (**Supp. Fig. 3A**). Since the phagocyte-bead interaction is dependent on these metrics, we calculated a phagocytosis score based on the percentage of cells that are bead positive multiplied by the median fluorescence signal (bead signal) of that population, as described in other work¹⁸⁻¹⁹.

Interestingly, both subclasses of IgG1 and IgG3 for both clones show potent Fc-mediated function compared to the negative control (Xolair, human IgG1 anti-IgE). This was observed in the percentage of cells that are interacting with the BQ1.1 spike-coated beads (bead⁺ cells), with all

single IgGs showing comparable performance in this metric (ranging from 20-22% bead⁺ cells) compared to the negative control (9% bead⁺ cells, **Fig. 3A**). Furthermore, we analyzed the amount of beads being phagocytosed in cells associated with beads by quantifying the bead signal. In this analysis, IgG3 Ab81 stood out as the most potent opsonin (mean bead signal of 18200), followed by Ab94 IgG3 (15100, **Fig. 3B**). Ab81 and Ab94 IgG1 outperformed the negative control as well with mean bead signals of 13600 and 13000 respectively compared to the negative control (12000). Finally, we analyzed the phagocytosis score to acquire a comprehensive overview of the bead-phagocyte interaction. This analysis shows that Ab81 IgG3 enhanced bead-uptake by the THP1-cells more than 4-fold compared to the negative control (4300 vs 1000) while Ab94 IgG3 showed similar activity with a 3.5-fold enhancement (3500 vs 1030, **Fig. 3C**). No difference was seen between the IgG subclass controls (**Fig. 3D**). The IgG1 versions of clones 81 and 94 were 2.7-fold more potent than the negative control, trailing their IgG3 variants (2800 and 2700 respectively). Taken together, the results show that the opsonic clones 81 and 94 have strong Fc-mediated function against the BQ1.1 variant and that the IgG3 versions are, as the case with Wuhan, more potent opsonins.

Cocktail of an anti-RBD and an anti-NTD mAb shows potent Fc-mediated phagocytosis in both IgG1 and IgG3 subclasses

In a previous study, we showed that combining a potent anti-NTD antibody (clone 94) with that of a potent anti-RBD (clone 81) generated a superior opsonic performance¹⁰. We named this cocktail DuomAb, and the IgG3 version of these mAbs showed the largest Fc-mediated effector functions against the Wuhan strain¹⁰. Having established potent function in both subclasses (IgG1 and IgG3) of Ab81 and Ab94 against BQ1.1 (the circulating variant in Sweden during the fall of 2022), we set out to test whether their potency could be enhanced by combining them in the same 2-antibody cocktail as done against the Wuhan strain (DuomAb) but against BQ1.1.

We performed similar experiments by incubating opsonized spike-beads with THP-1 cells. Only the DuomAb IgG3 outperformed the single mAbs at equivalent concentrations. DuomAb IgG1 and the individual mAbs Ab81 IgG1 and Ab94 IgG1 had very similar associating cells (24.9%, 19.8%, and 20.3% respectively, **Fig. 3E**). There was an increase in association with DuomAb IgG3 (DuomAb IgG3 = 31.3%, Ab81 IgG3 = 22.0%, Ab94 IgG3 = 21.5%, **Fig. 3E**). When looking at phagocytosis scores there was a difference for the DuomAb IgG1 vs. single IgG1 (DuomAb IgG1 = 3900, Ab81 IgG1 = 2800 and Ab94 IgG1 = 2700, **Fig. 3F**). Similarly as with percentage of bead⁺ cells, DuomAb IgG3 had higher phagocytosis score compared to single IgG3 mAbs (DuomAb IgG3 = 5000, Ab81 IgG3 = 4300, Ab94 IgG3 = 3500, **Fig. 3F**). Compared to the negative control, DuomAb IgG3 was the most potent opsonin, with a 5-fold higher phagocytosis score (**Fig. 3F-G**).

Furthermore, since the ratio of prey (spike-beads in this case) is a known factor influencing phagocytosis outcome²⁰, we decided to vary the ratio of prey to phagocytes, the multiplicity of prey (MOP), as described previously²⁰. We plotted the MOP against percentage associating cells and used non-linear regression analysis to generate the MOP₅₀ value (equivalent to EC₅₀) to compare the cocktails vs. single mAbs. A lower MOP₅₀ value signifies an antibody that mediates more efficient phagocyte-prey interaction and is a more potent mediator of Fc-dependent phagocytosis. We observed that, while Ab81 and Ab94 IgG3 are both more efficient than the control (Ab81 IgG3 MOP₅₀ = 9, Ab94 IgG3 = 8, Control MOP₅₀ = 48, **Fig. 3H**), they are both most effective when used in conjunction as DuomAb IgG3 (MOP₅₀ = 6, **Fig. 3H**). Similarly as for the IgG3 variants, the IgG1 single mAbs outperformed the negative control (Ab81 IgG1 MOP₅₀ = 14, Ab94 IgG1 = 12, Control MOP₅₀ = 48, **Fig. 3I**) but were less efficient than their IgG3 counterparts. Here, the DuomAb IgG1 cocktail was more effective than both individual IgG1s (MOP₅₀ = 9). However, although DuomAb IgG1 was more potent than its IgG1's single mAbs, it was not more effective than Ab94 IgG3 and was inferior to both DuomAb IgG3 and Ab81 IgG3, respectively (**Fig. 3H-J**). Further analysis indicates that DuomAb IgG3 exhibits a cooperative function with a Hill-slope constant (n_H) above 1 (**Fig. 3K**). We did not observe such cooperative functions for the individual mAbs nor DuomAb IgG1. Finally, to extend our findings with the potent functions of DuomAb IgG3 compared to IgG1,

we performed similar experiments with XBB spike trimer-coated beads. These results reinforced our findings with the Wuhan and BQ1.1 strain, with IgG3 DuomAb being highly opsonic compared to IgG1 DuomAb in terms of association (62.7% vs 43.5) and overall phagocytosis performance (5130 vs 2440) (**Fig. 3L**).

Taken together, our results show that both clones Ab81 and Ab94 exhibit potent Fc-mediated function against BQ1.1 and that engineering these clones in the IgG3 subclass and combining them in a 2-antibody cocktail generates even more potent functions against XBB and BQ.1.1. Since these nnAbs have demonstrated strong protectiveness against stringent infection in K18-hACE2 mice, our data suggests they would be promising candidates for therapy against BQ1.1, XBB and other variants.

Discussion

Monoclonal antibody therapy against SARS-CoV-2 was successful in the initial phase of the pandemic². These antibody therapeutics neutralized antibodies that targeted specific RBD sites important for interaction with the ACE2-receptor. Unfortunately, mutated variants such as Omicron and its sub-lineages showed extensive mutations in these neutralizing epitopes, leading all clinically approved mAbs to lose binding and function⁴⁻⁶. Although many neutralizing mAbs generated initially against the Wuhan strain lost binding and function, researchers have successfully developed mAbs that neutralize the variants currently circulating⁷⁻⁸. However, when testing these nAbs against emerging variants, several studies have shown a reduced neutralizing effect (IC₅₀) compared to the Wuhan strain in the newer variants^{7-8, 21-22}. It appears likely that the trend will continue and that these nAbs will also eventually lose neutralizing capacity.

Neutralizing antibodies constitute a fraction of the adaptive antibody response generated against the SARS-CoV-2 virus. Most antibodies that bind to the spike antigen are not neutralizing²³. However, this does not necessarily imply that they do not serve any protective immune function. In previous work, we showed that all our antibody clones that bind to the spike protein promoted efficient phagocytosis through Fc-effector functions⁹. The importance of Fc-mediated effector functions of anti-spike mAbs has for long not been the focus of the scientific community as an important immune mechanism against severe disease by SARS-CoV-2. For other viral pathogens such as adenovirus²⁴, West Nile virus²⁵, HIV-1²⁶, RSV²⁷⁻²⁸, Human CMV²⁹, and Influenza virus³⁰⁻³², antibody Fc-mediated effector functions are important for viral clearance. Thus, it is not surprising that more evidence is emerging showing that non-neutralizing antibodies mediate protective Fc-effector function against SARS-CoV-2. The evidence ranges from work with polyclonal antibodies from convalescent patients^{11,14}, modification of amino acids impacting Fc-effector function of neutralizing antibodies¹² to non-neutralizing antibodies^{6,10}.

Here, we show that two nnAbs, Ab81 and Ab94, retain high-affinity binding against variants up to XBB.1.5 and BQ1.1 and have strong Fc-mediated function against BQ1.1 and XBB. Although we do not know which epitope in the RBD-specific clone 81 binds, our experimental data shows that it has not been much influenced by the current mutations in the RBD (up until BQ.1.1 and XBB.1.5). Ab94, on the other hand, binds a seemingly conserved epitope since it binds to XBB equivalent to WT spike and 5-fold better to BQ.1.1. In addition, there have not been any mutations in the residues it binds (G35-F43) in any of the current circulating variants⁶.

Both Ab81 and Ab94 were derived from Swedish patients in March 2020⁹, early during the pandemic. No variants of concern had yet surfaced³³. This means that these antibodies did not arise as a host response to any spike variants and that it is likely that the human immune system has been able to generate such protective nnAbs in response to SARS-CoV-2 infections all through the pandemic. This ability is likely common also in response to commonly used spike-based vaccines. The ability to generate protective antibodies against conserved non-neutralizing epitopes contributes to the ability of vaccination using early vaccine variants and prior, early infections to

remain relatively effective in preventing serious disease, also following infection with emerging viral variants³⁴.

Of our mAbs tested previously¹⁰, Ab94 IgG3 stood out as the most potent, closely followed by Ab81 IgG3. The location of its binding site could explain Ab94's potent Fc-mediated effector functions. In a previous study, an anti-NTD neutralizing antibody targeting the antigen supersite 1 (residues 14 to 26) exhibited strong Fc-mediated effector functions, which the authors attribute to a favorable orientation of the Fc relative to Fc-gamma receptors¹⁷. We propose that Ab94 also binds in a favorable orientation, enabling efficient crosslinking to Fc-gamma receptors due to the proximity to the antigen supersite 1 on the NTD. This potency is likely further enhanced by the flexibility associated with IgG3's hinge, promoting more efficient Fc-FcR interactions. Such potent Fc-mediated functions of Ab94 and Ab81 could explain why they show a protective effect *in vivo* while another nnAb did not show this protective effect¹³. Not all opsonic nnAbs are necessarily protective¹³, and of our panel of 8 nnAbs, Ab81 and Ab94 stood out as far more potent opsonizers¹⁰.

In our most recent work, Ab94 and Ab81 were both protective against an infection of authentic SARS-CoV-2 in K18-hACE2 mice in a prophylactic setting¹⁰. This is even more striking when considering that survival benefits were shown in a model suboptimal for human IgGs effector functions since human IgG (especially IgG3) promotes weaker phagocytosis by mouse phagocytes³⁵⁻³⁶. Additionally, human IgG3 has a much shorter half-life in mouse circulation than human IgG1³⁷. The protective effects shown by these two mAbs could, therefore, be underestimated in a human setting. Furthermore, Ab94 was also shown to be protective in a therapeutic model, where it was comparable to clone 59, a potent nAb with IC₅₀ of 19 ng/mL⁹. This comparison suggests that the protective benefit of nnAbs is comparable to that of nAbs. It is also worth noting that the mice were inoculated with a lethal dose of SARS-CoV-2 in both infection models, 10⁵ PFU⁹⁻¹⁰. This dose is higher than that used in most studies that have shown the protective benefits of nAbs. Most researchers have tested the nAbs protective effect against a dose ranging from 10³ PFU to 10⁴^{7-8,12,38-40}, which are sublethal in comparison⁴¹. Thus, not only do Ab81 and Ab94 retain binding and function against the new variants, but their Fc-mediated function has also been shown to be protective against death and weight loss in infection models where mice were challenged with a higher, and lethal viral dose compared to those commonly used to assess nAb protectiveness^{7-8, 2, 38-41}.

Although we recently showed that our opsonic mAbs are protective against the Wuhan strain in an K18-hACE2 mouse model, we did not perform similar experiments with the newer variants in this study. Instead, we showed that these antibodies retained equivalent binding to all variants tested and retained potent immune function by using the BQ1.1 and XBB variants as proof of concept. Taken together, our work with the nnAbs Ab81 and Ab94 shows the promise of using nnAbs as both prophylactic and therapeutic therapy against the current and future SARS-CoV-2 variants. Combining these nnAbs with potent nAbs could be one promising strategy to increase protective effects in vulnerable patients against the current and future variants.

Materials and Methods

Cell culture and antibody production

Expi293F suspension cells were purchased from Gibco (ThermoFisher) and routinely cultured in 125 ml Erlenmeyer flasks (Nalgene) in 30 ml Expi293 medium (Gibco) in an Eppendorf s41i shaker incubator at 37°C, 8 % CO₂, 120 rpm. Cells were routinely passed and split to a density of 0.5 x 10⁶ cells/ml every 3 to 4 days. The day before transfection, the cells were seeded at a density of 2 x 10⁶ cells/ml. The next day, cells were seeded at 7.5 x 10⁷ cells in 25.5 ml Expi293 medium. Transfection with heavy and light chain plasmids was performed using the Expifectamine293 kit (Gibco) according to the manufacturer's instructions. The plasmids for the heavy chains were generated previously⁹⁻¹⁰. Briefly, 20 µg of heavy and light chain plasmid, respectively, were mixed with 2.8 ml OptiMEM (Gibco) and 100 µl Expifectamine and incubated at room temperature for 15 minutes. Afterward, the transfection mix was added to the Expi293F cells. The following day, 1.5

ml of enhancer 1 and 0.15 ml of enhancer 2 (both from the Expifectamine293 kit) were added, and the cells were cultured for another 72 hours.

The cells were removed from the cell culture medium by centrifugation (400 x g, 5 min), and the supernatant was transferred to a new tube. To capture the IgGs from the medium, protein G sepharose 4 Fast Flow (Cytiva) was added to the medium and incubated end-over-end at room temperature for 2 hours. The beads were collected by running the medium bead mix through a gravity flow chromatography column (Biorad) and washed twice with 50 ml PBS. The antibodies were eluted using 5 ml HCl-glycine (0.1 M, pH 2.7). Tris (1 M, pH 8, 1 ml) was used to neutralize the pH. The buffer was exchanged to PBS using Amicon Ultra-15 centrifugal filters (Sigma) with a molecular cut-off of 30,000 Da. The concentration and quality of the purified antibodies were spectrophotometrically measured with the IgG setting of the Nanodrop (Denovix).

Generation of Spike-coated beads

Wuhan Spike-protein was generated by transfecting Expi293F cells with 40 µg plasmid containing the gene for the Spike protein (CS/PP Spike encoding a secretable version of the protein was used to allow purification from cell culture supernatants), donated previously to us by Dr. Florian Krammer's lab⁵. Omicron (#158-40589-V08H26-100), BA.2 (#158-40589-V08H28-100), BA.4 (#158-40589-V08H32-100), BA.5 (#158-40589-V08H33-100), XBB (#158-40589-V08H40-100) and BQ1.1(158-40589-V08H41-100) was acquired from Nordic biosite. 25 µg of Spike protein was biotinylated according to the instructions of EZ-Link™ Micro Sulfo-NHS-LC Biotinylation Kit (ThermoFisher). Then fluorescent (APC) streptavidin microsphere beads (63µl from stock) (1 µm, Bangs Laboratories) were conjugated with the biotinylated Spike protein (25 µg) according to the manufacturer's instructions as done previously⁹⁻¹⁰.

Flow cytometry-based avidity measurements

The binding assays were performed in a 96-well plate, pre-coated with 200 µl of 2% BSA (in PBS) at 37 degrees for 30 minutes. 250,000 Spike-coated beads were used in all wells, with an antibody concentration of 1 µg per ml. The beads were opsonized at a volume of 100 µl in 1X PBS at 37 °C for 30 min on a shaking heat block. The wells were washed twice with PBS. To assess antibody binding to Spike beads, 50 µl of (1:500 diluted) a Fab-specific fluorescent secondary antibody (#109-546-097, Jackson ImmunoResearch) was used to create a fluorescent signal. The secondary antibody was left to incubate with the Spike-bead antibody complex at 37 °Cs for 30 minutes on a shaking heat block. 100 µl of PBS was added to the wells before analysis in the flow cytometer. The beads were analyzed using a Beckman Coulter Cytotflex flow cytometer, which acquired 10000 beads per sample. The data was processed using Flowjo. The gate for Spike beads was set based on forward and side scatter (**Supp. Fig 2A**). The gate for Spike beads positive for antibodies was set based on reactivity to a non-reactive IgG control mAb.

SPR kinetic assay

To study binding kinetics to Spike trimer or NTD we immobilized A High Capacity Amine Sensor chip (Bruker) was immobilized with Anti-human IgG (Fc) antibody (Cytiva BR-1008-39) at 25 µg/ml in 10 mM sodium acetate buffer pH 5 at flow rate 10 µl/min and contacting 300s. This was done in a MASS-16 biosensor instrument (Bruker). Running buffer PBS + 0,05% Tween20. Antigens were acquired from Nordic biosite (Omicron#158-40589-V08H26-100,BA.2#158-40589-V08H28-100,BA.4 #158-40589-V08H32-100,BA.5#158-40589-V08H33-100,XBB#158-40589-V08H40-100, XBB.1.5 #158-40592-v08h146-100, BQ.1.1 #158-40589-V08H41-100).The antibodies were diluted in PBS and injected over the surface for 90s at 10 µL/min. The running buffer was PBS with 0.01% Tween 20. All variants of the Spike trimer were analyzed at 20 nM to 1.25 nM concentrations. The XBB.1.5 RBD was analyzed at concentrations ranging between 20 nM to 1.25 nM as well. The antigens were injected at these concentrations and were allowed to interact with the sensor for 2 minutes, with flow rate 30 µl/min, followed by a dissociation for 6 minutes. After each cycle the surface was regenerated with 3M MgCl. All experiments were performed once. The data was

analyzed using Sierra Analyser software version 3.4.3 (Bruker) program to determine apparent dissociation constants (K_D) and constant rates (k_A)

Flow cytometry-based phagocytosis assays

THP-1 cells (Sigma-Aldrich) were cultured as described previously⁵. In all experiments, 1×10^5 THP-1 cells were used. In the experiments the ratio of cells to beads ranged from 6.25 to 25 for the curves (MOP 6.25-25) and MOP 25 for the XBB experiments. For all experiments, the Spike beads were opsonized with 2.5 $\mu\text{g/ml}$ of antibodies in a volume of 100 μl of Sodium media (pH adjusted to 7.3 with NaOH; 5.6 mM glucose, 10.8 mM, 127 mM NaCl, KCl, 2.4 mM KH_2PO_4 , 1.6 mM MgSO_4 , 10 mM HEPES, 1.8 mM CaCl_2). Opsonizations were performed for 30 minutes at 37 °C on a shaking heat block (300 RPM) in a volume of 100 μl . During this incubation period, THP-1 cells were counted (using a Bürker chamber) and medium was exchanged from RPMI to Sodium medium. THP-1 cells (50 μl , $2 \times 10^6/\text{ml}$) were added to each well and the cells were allowed to phagocytose beads for 30 minutes at 37 °C on a shaking heat block (300 RPM). The 96-well plate was then incubated on ice for 15 minutes and analyzed directly in a Beckman Coulter Cytoflex flow cytometer. A gate for THP-1 cells was set up based on their forward and side scatter. The gate for association was set with a negative control of cells only. The analysis stopped after 5000 events were captured in the THP-1-gate. The data was analyzed in the program Flowjo by setting similar gates as described above (**Supp Fig. 3A**). The Flowjo-processed data was further analyzed in GraphPad Prism where the bead signal (APC-A) of the THP-1 gate association gate, percentage of associating cells and phagocytosis score were plotted to compare the different antibodies. Phagocytosis score was calculated based on the percentage of bead⁺ cells (associating cells) multiplied by the median fluorescence intensity (APC-A) of that population as described previously¹⁸⁻¹⁹.

Statistical analysis

Statistical analysis was performed in GraphPad Prism. For comparisons between clones when more than 2 treatments were analyzed, a one-way ANOVA with multiple comparisons test was used, with correction for multiple comparisons with Dunnes' test or Tukey's depending on the comparisons being made.

Bioinformatics

Analysis of spike mutations was performed using the lineage comparison tool at GSAID described recently⁴² by aligning the strains of interest with that of a reference strain B.1.

Acknowledgments

We acknowledge funding from the Swedish Research Council, Crafoord Foundation, and Knut and Alice Wallenberg Foundations, and support from an infrastructure grant from the Faculty of Engineering, Lund University.

References

1. Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. *Nat. Rev. Microbiol.* **19**, 141–154 (2021).
2. Chen, P. *et al.* SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. *N. Engl. J. Med.* **384**, 229–237 (2021).
3. Tortorici, M. A. *et al.* Ultrapotent human antibodies protect against SARS-CoV-2. *Science*. **20**;370(6519):950-957 (2020). doi: 10.1126/science.abe3354
4. VanBlargan, L. A. *et al.* An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat. Med.* **28**, 490–495 (2022).
5. Cao, Y., Wang, J., Jian, F. *et al.* Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* **602**, 657–663 (2022). <https://doi.org/10.1038/s41586-021-04385-3>
6. Wang *et al.* Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants *Cell* **186**, 279–286 January 19, 2023 <https://doi.org/10.1016/j.cell.2022.12.018>
7. Filippo Bianchini *et al.* Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. *Sci Immunol.* **8**, eade0958(2023). DOI: [10.1126/sciimmunol.ade0958](https://doi.org/10.1126/sciimmunol.ade0958)
8. Rouet, R., Henry, J.Y., Johansen, M.D. *et al.* Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. *Nat Commun* **14**, 687 (2023). <https://doi.org/10.1038/s41467-023-36295-5>
9. Bahnan, W. *et al.* Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2. *Front. Immunol.* **12**, 1–17 (2022).
10. Izadi A *et al.* Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization. *Proc Natl Acad Sci U S A.* 2023 Apr 11;120(15):e2217590120. doi: 10.1073/pnas.2217590120.
11. Mackin, S.R., Desai, P., Whitener, B.M. *et al.* Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. *Nat Microbiol* **8**, 569–580 (2023). <https://doi.org/10.1038/s41564-023-01359-1>
12. Winkler, E *et al.* Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. *Cell*. 2021 Apr 1;184(7):1804-1820.e16. doi: 10.1016/j.cell.2021.02.026.
13. Beaudoin-Bussi eres, G. *et al.* A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. *Cell Rep.* **38**, (2022).
14. Ullah, I *et al.* The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. *Cell Rep Med.* 2023 Jan 17;4(1):100893. doi: 10.1016/j.xcrm.2022.100893
15. Kaplonek, P. *et al.* mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. *Immunity* **55**, 355-365.e4 (2022).

16. Cerutti, G. *et al.* Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. *Cell Host Microbe* **29**, 819-833.e7 (2021).
17. Wang, Z. *et al.* Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. *Immunity* **55**, 998-1012.e8 (2022).
18. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against *Leishmania major*. *Nat Med*. 2007;**13**:843–50
19. Ackerman ME *et al.* A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. *J Immunol Methods*. 2011 Mar 7;**366**(1-2):8-19. doi: 10.1016/j.jim.2010.12.016
20. T. de Neergaard, M. Sundwall, S. Wrighton, P. Nordenfelt, High-sensitivity assessment of phagocytosis by persistent association-based normalization. *J. Immunol.* **206**, 214–224 (2021).
21. J. Guenthoer *et al.* Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection. *Proc Natl Acad Sci U S A*. 2023 May 120; **23**.
22. Y. Feng *et al.* Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine. *Sci. Transl. Med.* **15**, eadg7404(2023). DOI: [10.1126/scitranslmed.adg7404](https://doi.org/10.1126/scitranslmed.adg7404)
23. S. Yamayoshi *et al.*, Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. *EClin. Med.* **32**, 100734 (2021).
24. Zaiss AK *et al.* Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response. *J Immunol.* (2009) **182**:7058–68
25. Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcγ receptor and complement-dependent effector mechanisms. *J Virol*. 2011 Nov;**85**(22):11567-80. doi: 10.1128/JVI.05859-11.
26. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, *et al.* Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. *Cell*. (2013) **155**:531–9. 10.1016/j.cell.2013.09.06
27. Corbeil S, Seguin C, Trudel M. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. *Vaccine*. 1996 Apr;**14**(6):521-5. doi: 10.1016/0264-410x(95)00222-m.
28. Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')₂ components mediates reduced pulmonary inflammation in mice. *J Gen Virol.* (2009) **90**(Pt 5):1119–23. 10.1099/vir.0.009308-0
29. Nelson CS *et al.* HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. *Proc Natl Acad Sci U S A*. 2018 Jun **12**;115(24):6267-6272. doi: 10.1073/pnas.1800177115.

30. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus *in vivo*. *Nat Med*. (2014) **20**:143–51. [10.1038/nm.3443](https://doi.org/10.1038/nm.3443)
31. Henry Dunand CJ. et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. *Cell Host Microbe*. (2016) **19**:800–13. [10.1016/j.chom.2016.05.014](https://doi.org/10.1016/j.chom.2016.05.014)
32. Vanderven HA. et al. Fc functional antibodies in humans with severe H7N9 and seasonal influenza. *JCI Insight*. (2017) **2**:92750. [10.1172/jci.insight.92750](https://doi.org/10.1172/jci.insight.92750)
33. Public Health Agency of Sweden. Veckorapport om covid-19, vecka 51. 2020 dec. <https://www.folkhalsomyndigheten.se/globalassets/statistik-uppfoljning/smittsamma-sjukdomar/veckorapporter-covid-19/2020/covid-19-veckorapport-vecka-51-final.pdf>.
34. Lau, J.J., Cheng, S.M.S., Leung, K. et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. *Nat Med* **29**, 348–357 (2023). <https://doi.org/10.1038/s41591-023-02219-5>
35. Z. Steplewski et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. *Proc. Natl. Acad. Sci. U.S.A.* **85**, 4852–4856 (1988).
36. M. B. Overdijk, Crosstalk between human IgG isotypes and murine effector cells. *J. Immunol.* **189**, 3430–3438 (2012), <https://doi.org/10.4049/jimmunol.1200356>.
37. R. Bazin et al., Use of hu-IgG-SCID mice to evaluate the *in vivo* stability of human monoclonal IgG antibodies. *J Immunol Methods* **172**, 209–217 (1994), [https://doi.org/10.1016/0022-1759\(94\)90108-2](https://doi.org/10.1016/0022-1759(94)90108-2).
38. Yamin, R., Jones, A.T., Hoffmann, HH. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. *Nature* **599**, 465–470 (2021). <https://doi.org/10.1038/s41586-021-04017-w>
39. Dissupt V et al. Low-dose *in vivo* protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. *Nat Immunol.* 2021 Dec;**22**(12):1503-1514. doi: [10.1038/s41590-021-01068-z](https://doi.org/10.1038/s41590-021-01068-z).
40. Zheng, J., Wong, LY.R., Li, K. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. *Nature* **589**, 603–607 (2021). <https://doi.org/10.1038/s41586-020-2943-z>
41. Dong An et al. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5–based COVID-19 vaccine. *Sci. Adv.* **7**, eabi5246(2021). DOI: [10.1126/sciadv.abi5246](https://doi.org/10.1126/sciadv.abi5246)
42. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Karthik Gangavarapu et al. *Nature Methods* (2023). doi: [10.1038/s41592-023-01769-3](https://doi.org/10.1038/s41592-023-01769-3)
43. Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Velesler, D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **2020**, *181*, 281–292, <https://doi.org/10.1016/j.cell.2020.02.058>.

Figures

Figure 1




Figure 1. The spike protein has extensive mutations in NTD and RBD domain up until EG5.1 and XBB1.16

A-B Spike trimer protein model with the RBD colored in green, NTD in purple, and the S2 domain in light blue. PDB ID: 6vxx⁴³ **C** Amino acid sequence of the spike protein of the Wuhan strain with

mutated residues highlighted in red. **D** Table summarizing antibody epitope specificity and neutralizing ability. **E** Wuhan spike protein was conjugated to microsphere beads and used as a model for SARS-CoV-2 virions. The spike-coated beads were opsonized with anti-spike mAbs. Detection of IgG-positive beads was done by adding an anti-IgG secondary, which was labeled with Alexa Flour 488. The binding of anti-spike mAbs to spike-coated beads was done by flow cytometry. The Y-axis shows the percentage of IgG+ beads. The red-colored antibodies are non-neutralizing (nnAbs), and the blue are neutralizing antibodies (nAbs). Figure **F** depicts the reactivity of anti-spike antibodies against Omicron, **G** against BA.2, **H** against BA.4, and **I** against BA.5. In **E-H**, the percentage of binding was normalized to the background of Wuhan binding to Ab11. Statistical analysis was performed with one-way ANOVA with multiple comparisons against IgG control and corrected with Dunne's correction test. ** denotes P-value < 0.01, * denotes P-value < 0.05 and P-value > 0.05 is ns.

Figure 2




Figure 2. Binding kinetics with surface plasmon resonance reveal intact nnAb binding to spike variants

Surface plasmon resonance (SPR) -based binding kinetics assay with nnAbs against the spike trimer as ligand with WT, Omicron, BA.2, BA.4, and BA.5. IgG concentration was kept constant on the sensor chip. In **A** IgG3 Ab66 is used in **B** IgG3 Ab77, in **C** IgG3 Ab81 and in **D** IgG3 Ab94. The spike concentration used ranged from 20-1.25 nM. **E** Table with K_D -values and K_A for the nnAb antibodies against the spike variants. **F** SPR kinetic assay with clones 81 and 94 against XBB and BQ.1.1 spike trimer and XBB.1.5 RBD. **G** Table with K_D -values and K_A for the nnAb antibodies against the spike variants.

Figure 3




Figure 3. Both IgG1 and IgG3 subclasses of clones 81 and 94 show potent Fc-mediated phagocytosis against the BQ1.1 and XBB variants

Phagocytosis of spike-coated beads by the THP-1 cells was analyzed by flow cytometry. In **A-C**, **E-F** experiments were done at MOP 12.5 (100.000 THP1 cells, 1.25 million beads) with 2.5 ug/mL of antibodies to opsonize the spike beads. In short, THP1 cells were gated for bead signal (**Supp Fig. 3**) to generate % of bead positive cells (dubbed association) seen in **A**. The bead-positive cells

were further analyzed for bead signal (Median fluorescence signal, MFI), a metric for the quantity of beads. By using association and MFI, a phagocytosis score was produced (% association multiplied by MFI/100). **A.** The percentage of bead-positive cells on the Y-axis with the treatments on the X-axis. **B** The bead signal (APC) for the bead-positive population on the Y-axis. **C** Phagocytosis score is shown on the Y-axis. **D** Shows the phagocytosis score for IgG subclass controls at MOP 25; no difference was observed. **E.** E Shows the percentage of bead-positive cells on the Y-axis at MOP 12.5 (100,000 cells, 2.5 million beads). **F** Depicts the phagocytosis score on the Y-axis at MOP 25. **G** Table summarizing the mean values from the experiments seen in A-F. **H-J** The graphs show association (bead⁺ cells) as a function of MOP (ranging from 25-6.25), and an EC⁵⁰ was generated by a non-linear regression analysis (named MOP⁵⁰). **H** Shows the differences between IgG3 single mAbs vs. cocktail. **I** Comparison of the differences between IgG1 single mAbs vs. IgG1 cocktails. **J** Shows the differences between IgG1 and IgG3 cocktails. In **K**, the MOP50 for each treatment is shown in addition to the Hill-slope value. In **L**, association and phagocytosis score by THP1 cells incubated with XBB spike-coated beads at MOP 25 is shown. In A-C, E-K, data are from 5 independent experiments. In D, it's from three independent experiments, while for L, it's from 4. In all figures, the mean is shown, and the error bars are SEM. Statistical analysis was performed with one-way ANOVA with multiple comparisons corrected with Dunnett's correction test for A-C and E-F compared against IgG control, while for L, comparisons were made for all treatments and corrected with Tukey's correction test. ** denotes P-value < 0.01, * denotes P-value < 0.05 and P-value > 0.05 is ns.